全文获取类型
| 收费全文 | 7565篇 |
| 免费 | 373篇 |
| 国内免费 | 36篇 |
学科分类
| 医药卫生 | 7974篇 |
出版年
| 2023年 | 60篇 |
| 2022年 | 66篇 |
| 2021年 | 311篇 |
| 2020年 | 181篇 |
| 2019年 | 222篇 |
| 2018年 | 268篇 |
| 2017年 | 176篇 |
| 2016年 | 241篇 |
| 2015年 | 262篇 |
| 2014年 | 355篇 |
| 2013年 | 406篇 |
| 2012年 | 615篇 |
| 2011年 | 604篇 |
| 2010年 | 341篇 |
| 2009年 | 271篇 |
| 2008年 | 459篇 |
| 2007年 | 426篇 |
| 2006年 | 422篇 |
| 2005年 | 366篇 |
| 2004年 | 298篇 |
| 2003年 | 284篇 |
| 2002年 | 195篇 |
| 2001年 | 118篇 |
| 2000年 | 118篇 |
| 1999年 | 106篇 |
| 1998年 | 60篇 |
| 1997年 | 34篇 |
| 1996年 | 24篇 |
| 1995年 | 27篇 |
| 1994年 | 26篇 |
| 1993年 | 31篇 |
| 1992年 | 62篇 |
| 1991年 | 41篇 |
| 1990年 | 35篇 |
| 1989年 | 61篇 |
| 1988年 | 48篇 |
| 1987年 | 23篇 |
| 1986年 | 32篇 |
| 1985年 | 33篇 |
| 1984年 | 26篇 |
| 1983年 | 37篇 |
| 1981年 | 13篇 |
| 1980年 | 19篇 |
| 1979年 | 24篇 |
| 1978年 | 14篇 |
| 1975年 | 11篇 |
| 1973年 | 18篇 |
| 1972年 | 13篇 |
| 1971年 | 12篇 |
| 1970年 | 13篇 |
排序方式： 共有7974条查询结果，搜索用时 78 毫秒
1.
2.
3.
Uday Yanamandra Prateek Deo Kamal Kant Sahu Ram Vasudevan Nampoothiri Nalini Gupta Anusree Prabhakaran Deb Prasad Dhibhar Alka Khadwal Gaurav Prakash Man Upadesh Singh Sachdeva Deepesh Lad Neelam Varma Subhash Varma Pankaj Malhotra 《Clinical Lymphoma, Myeloma & Leukemia》2019,19(3):183-189.e1
Background
Multiple myeloma (MM) is a hematologic malignancy of plasma cell origin. MM primarily affects bone marrow, but extramedullary sites can also be involved. Myelomatous pleural effusion (MPE) is an atypical and rare complication of MM. We aimed to systematically study the incidence and clinicopathologic profile of patients with MPE in a real-world setting.Patients and Methods
In this retrospective study, 415 consecutive patients with MM managed at a tertiary care center in North India during a study period of January 1, 2010 to December 31, 2015 were evaluated for MPE. The patients with MPE were analyzed for their clinical profile, diagnosis, treatment, and outcomes.Results
Of these 415 patients, 11 (2.65%) patients had MPE. The median age of the study population was 50 years with male preponderance. The majority of these patients had immunoglobin (Ig)G Kappa disease. All patients had higher than International Staging System stage I disease. MPE was a presenting feature at MM diagnosis in 45.45% (n = 5) of the patients, whereas the rest developed MPE during follow-up. MPE presented predominantly (81.8%) as a unilateral effusion. Concurrent extramedullary involvement at other site was seen in 45.45% (n = 5), with 3 (27%) patients having concurrent myelomatous ascites. Six of these were managed aggressively, whereas 5 patients opted for palliation. The outcomes were dismal (90.9% mortality), with a median survival of 2.47 months.Conclusion
MPE is a rare entity, and positive outcomes of therapy remain low with dismal prognosis. 相似文献4.
5.
Joseph F. Levy Rahul Khairnar Alexander V. Louie Timothy N. Showalter C. Daniel Mullins Mark V. Mishra 《Practical radiation oncology》2019,9(2):e172-e179
Purpose
A hydrogel rectal spacer (HRS) is a medical device that is approved by the U.S. Food and Drug Administration to increase the separation between the prostate and rectum. We conducted a cost-effectiveness analysis of HRS use for reduction in radiation therapy (RT) toxicities in patients with prostate cancer (PC) undergoing external beam RT (EBRT).Methods and Materials
A multistate Markov model was constructed from the U.S. payer perspective to examine the cost-effectiveness of HRS in men with localized PC receiving EBRT (EBRT alone vs EBRT + HRS). The subgroups analyzed included site of HRS placement (hospital outpatient, physician office, ambulatory surgery center) and proportion of patients with good baseline erectile function (EF). Data on EF, gastrointestinal and genitourinary toxicities incidence, and potential risks associated with HRS implantation were obtained from a recently published randomized clinical trial. Health utilities and costs were derived from the literature and the 2018 Physician Fee Schedule and were discounted 3% annually. Quality-adjusted life years (QALYs) and costs were modeled for a 5-year period from receipt of RT. Probabilistic sensitivity analysis and value-based threshold analyses were conducted.Results
The per-patient 5-year incremental cost for spacers administered in a hospital outpatient setting was $3578, and the incremental effectiveness was 0.0371 QALYs. The incremental cost-effectiveness ratio was $96,440/QALY for patients with PC undergoing HRS insertion in a hospital and $39,286/QALY for patients undergoing HRS insertion in an ambulatory facility. For men with good baseline EF, the incremental cost-effectiveness ratio was $35,548/QALY and $9627/QALY in hospital outpatient and ambulatory facility settings, respectively.Conclusions
Based on the current Medicare Physician Fee Schedule, HRS is cost-effective at a willingness to pay threshold of $100,000. These results contain substantial uncertainty, suggesting more evidence is needed to refine future decision-making. 相似文献6.
Gaurav Kumar Pankaj Paliwal Sumedha Mukherjee Nishant Patnaik Sairam Krishnamurthy 《Xenobiotica; the fate of foreign compounds in biological systems》2019,49(3):339-345
1. The present study is designed to investigate the brain distribution and plasma pharmacokinetics profiles of chlorogenic acid (CGA) after intranasal administration in Charles–Foster rats to evaluate whether the CGA molecules are transported directly via the nose-to-brain path.
2. The CGA is administered intravenously (IV) and intranasally (IN) at the dose of 10?mg/kg. Further, its concentration in the plasma, cerebrospinal fluid (CSF) and the whole brain is analyzed by HPLC-UV method.
3. The study observes that CGA is rapidly absorbed in plasma with tmax of 1?min similar to IV route after IN administration. The peak plasma concentration and AUC0–24 are higher by 3.5 and 4.0 times respectively in IV administration, compared to IN delivery that represents the significant less systemic exposure of CGA in IN route.
4. However, the concentration of CGA in the brain is 4, 6.5, 5.3, 5.2 and 4.5 times higher at 30, 60, 120, 240 and 360?min, respectively in IN administration compared to IV administration. The exposure of CGA in the brain after IN administration (AUCbrain, IN) was significantly greater (4 times) as compared to the exposure of CGA in the brain (AUCbrain, IV) after IV administration reflecting significant brain uptake of CGA through nasal route. Therefore, IN delivery of CGA can be a promising approach for the treatment of stroke and neurodegenerative disorders. 相似文献
7.
Correa Alec Reginald Errol Mishra Puneeta Kabra Madhulika Gupta Neerja 《Indian journal of pediatrics》2020,87(3):175-178
Indian Journal of Pediatrics - To report a phenotypic series of eight patients of Beckwith-Wiedemann Syndrome (BWS) with abnormalities of 11p15.5 region to highlight the spectrum of phenotypic... 相似文献
8.
Annals of Surgical Oncology - 相似文献
9.
Metabolic abnormalities of gastrointestinal mucosa in celiac disease: An in vitro proton nuclear magnetic resonance spectroscopy study 
下载免费PDF全文
下载免费PDF全文 10.
Pankaj Kumar Mishra 《European journal of cardio-thoracic surgery》2006,29(5):861-2; author reply 862
